Margaret Strub
Allergy & Immunology · Seattle, WANPI 1528146123
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by GSK at 24.1% of the total. Reporting peaked in 2024 at $1,451 and has fallen 85.4% since, to $211 in 2025.
Across 212 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Sanofi$632
- Optinose US, Inc.$275
- Takeda Pharmaceuticals U.S.A., Inc.$248
- Boehringer Ingelheim$215
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,851100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 55 | $1,169 |
| AstraZeneca | 48 | $1,155 |
| Sanofi | 20 | $632 |
| Optinose US, Inc. | 24 | $275 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $248 |
| Boehringer Ingelheim | 9 | $215 |
| Grifols USA, LLC | 5 | $116 |
| Regeneron Healthcare Solutions, Inc. | 4 | $108 |
| Kaleo, Inc. | 4 | $87 |
| Amgen | 3 | $80 |
| Genentech USA, Inc. | 3 | $78 |
| Blueprint Medicines Corporation | 2 | $76 |
| AbbVie | 3 | $67 |
| Biocryst US Sales Co., LLC | 2 | $67 |
| LEO Pharma Inc. | 2 | $56 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Pharming Healthcare, Inc. | 2 | $52 |
| Novartis | 2 | $52 |
| Aimmune Therapeutics, Inc. | 2 | $51 |
| Incyte Corporation | 2 | $49 |
| Octapharma USA, Inc. | 2 | $44 |
| Alk-abello, Inc | 2 | $40 |
| Invivyd Inc | 1 | $33 |
| CSL Behring | 1 | $30 |
| Genentech, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$119
How this compares
$4,859 in reported general payments places this provider in the 65th percentile of 81 allergy & immunology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 25 | $101,441 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,709 |
| Montelukast Sodium | 18 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,169 | $15,70924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 81 allergy & immunology providers in Washington.
Other allergy & immunology in Seattle
- Frank VirantSeattle$107K
- Leonard AltmanSeattle$81K
- Daniel PetroniSeattle$68K
- Rahool DaveSeattle$42K
- Matthew AltmanSeattle$37K
- Gabriel MendozaSeattle$16K
- Kelly ColasSeattle$14K
- Jing Yi SunSeattle$11K
- Paul WilliamsSeattle$7K
- Susan XieSeattle$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.